DPP‑4 inhibitors

GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes

By MedXY 05/02/2026

New research comparing diabetes medications reveals GLP-1 receptor agonists lower heart failure hospitalization risk compared to DPP-4 inhibitors, while showing similar risk to SGLT-2 inhibitors in type 2 diabetes patients.

Diabetes & Endocrinology Internal Medicine news

Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes

By MedXY 02/04/2026

A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.

Diabetes & Endocrinology Nephrology news

Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes

By MedXY 02/03/2026

A randomized clinical study demonstrates that while SGLT2 inhibitors alone may induce urinary dysbiosis and increase pathogen risk, combining them with DPP-4 inhibitors restores a healthy urinary microbiota, potentially improving patient compliance and long-term therapeutic outcomes.

Dermatology Diabetes & Endocrinology news

SGLT2 Inhibitors Linked to Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes

By MedXY 11/01/2025

A nationwide Taiwanese active-comparator cohort found SGLT2 inhibitor use was associated with a lower incidence of new-onset atopic dermatitis compared with DPP‑4 inhibitors; the effect persisted across sensitivity analyses, showed a dose-response relation and was stronger in men.